Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record.

Recent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence

Clarke, Christina A., Glaser, Sally L., Uratsu, Connie S., Selby, Joseph V., Kushi, Larry H., Herrinton, Lisa J.·2006·Journal of Clinical Oncology

Abstract

TO THE EDITOR: Long-term use of estrogen- or progestincontaining hormone therapies (HT) is well recognized to be associated with increased risk of breast cancer both in observational studies and the Women’s Health Initiative (WHI) randomized trial. 1 After the early termination of the trial in July 2002 and the subsequent media coverage, reports from clinical series indicated immediate declines of 28% to 46% in prevalences of HT and estrogen-only (ET) use. 2,3 The population-level impact of these declines on breast cancer are uncertain given the 2- to 3-year lag time between diagnosis and data availability in cancer registries. To better understand the possible impact from changes in HT on breast cancer in larger populations, we compared recent secular trends in HT use and breast cancer incidence in available clinical and population-based data resources, including recently released cancer registry data for the year 2004. We calculated the annual prevalence of HT use and the annual incidence of invasive breast cancer for the period from 1994 to 2003 for women ages 50 to 74 years in Kaiser Permanente’s (Oakland, CA) Northern California region (KPNC), a large integrated health-delivery system from which computerized pharmacy, membership, and hospital cancer registry data were obtained. Women filling at least two prescriptions (generally constituting 90 days per prescription) of HT or ET in any calendar year were considered users for that year. First primary invasive breast cancer (International Classification of Disease–Oncology, 3rd edition [ICDO-3] 4 site 50.0-50.9) diagnoses were identified, with histologic subtypes defined as ductal (ICD-O-3 codes 8500), or “with lobular component” (ICD-O-3 codes 8520, 8522, 8524). Yearly denominators included women who were KPNC members for at least 11 months of

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.08.6504

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 160

Metadata

Authors
Clarke, C. A., Glaser, S. L., Uratsu, C. S., Selby, J. V., Kushi, L. H., & Herrinton, L. J.
Venue
Journal of Clinical Oncology
Published
2006-11-20
Volume
24
Issue
33
Pages
e49-e50
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2163283029
Cited by
160
References
0
FWCI
14.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence. https://app.cochat.ai/papers/10.1200/jco.2006.08.6504
The paper
Clarke, C. A., Glaser, S. L., Uratsu, C. S., Selby, J. V., Kushi, L. H., & Herrinton, L. J. (2006). Recent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.08.6504

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.